Scientific Accomplishments

S.Glantz S.Hall
Program Leader: Joseph Guydish, PhD, MPH
Program Co-Leader: Stanton Glantz, PhD

Scientific Accomplishments

The accomplishments of the Program members revolve around five themes: (1) studies of nicotine and tobacco effects, metabolism and biomarkers, including secondhand smoke); (2) clinical interventions; (3) the economics of tobacco control; (4) the tobacco industry; and (5) descriptive and epidemiological studies. The top six highlights include:

  • Drs. Neal Benowitz and Sharon Hall determined that reduced nicotine cigarettes promote lower nicotine intake without increasing the intake of inhaled carcinogens. These findings suggest that a national policy to gradually reduce cigarette nicotine content could lead to a reduction in nicotine addiction in youth, without an increase in carcinogen intake in current smokers (Benowitz et al., Submitted; Benowitz et al., Cancer Epidemiol Biomarkers Prev, 2007).

  • Epidemiological and human laboratory research studies led by Dr. Stanton Glantz convincingly demonstrated that smoking in the movies is related to youth cigarette experimentation; these data supported a successful campaign to reduce depiction of smoking in movies (Shmueli et al., Am J Prev Med, 2010; Song et al., Am J Prev Med, 2007).

  • Led by Dr. Sharon Hall and colleagues Drs. Prochaska, and Munoz, two large controlled clinical trials of treatment of chronic smokers developed and evaluated an innovative cognitive behavioral intervention for smoking cessation; in both, long-term abstinence rates of approximately 50% were found, markedly exceeding the usual rates of 20% to 35%, thus providing a new option for such smokers (Hall et al., Am J Public Health, 2011; Hall et al., Addiction, 2009).

  • In a controlled clinical trial, Dr. Judith Prochaska and colleagues demonstrated that psychiatric patients with severe mental illness will accept smoking treatment; are responsive to an innovative intervention provided to them; will quit smoking at rates comparable to the general population; and do not experience an increase in psychiatric symptoms as a function of treatment or cigarette abstinence (Prochaska et al., 17th Annual Meeting of the Society for Research on Nicotine and Tobacco, 2011; Prochaska et al., Psychiatr Serv, 2009).

  • Dr. Perez-Stable and colleagues determined risk factors for smoking in youth in Latin America, the region in the world with the highest smoking rates, identifying mixed-race and indigenous youth as those at highest risk; completed studies that provide data for culturally appropriate interventions for these groups (Alderete et al., Anthropol Med, 2010; Alderete et al., Subst Use Misuse, 2009; Alderete et al., J Environ Public Health, 2010).

  • Dr. Sung documented the impact of tobacco use on economic burden and poverty in developing countries, especially China and India (John et al., Tob Control, 2009; John et al., Tob Control, 2011; Yang et al., Tob Control, 2011).